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Summary A total of 610 patients with small cell lung cancer were entered into a randomised trial designed
to assess the effect of duration of initial chemotherapy on survival. Patients were randomised to receive either
four or eight courses of cytotoxic chemotherapy with cyclophosphamide, vincristine and etoposide and also
randomised to receive, on disease progression, either second line chemotherapy (methotrexate and doxorubi-
cin) or symptomatic treatment only. In the whole study 196 (32.1%) had limited disease and 414 (67.9%)
extensive disease. During initial chemotherapy the response rate (complete and partial responses) after four
courses of treatment was 61% with no significant increase in patients receiving eight courses (63%). In those
randomised to receive relapse chemotherapy the response rate was improved slightly for those who had
originally received four courses of chemotherapy (25.6%) over those receiving eight (18.7%). The overall
results show that of the four possible treatment randomisations, four courses of chemotherapy alone is
inferior in terms of overall survival (30 weeks median survival) to the other three treatment options (39 weeks
median survival, P<0.01). In patients responding to initial chemotherapy the disadvantage of four courses of
chemotherapy alone was apparent (median survival of 40 weeks versus 49 weeks, P=0.003) but not if drug
treatment was given on relapse. The study shows that limiting treatment to four courses of chemotherapy
alone is associated with inferior survival, but this is not the case if chemotherapy is given at relapse.
Although combination chemotherapy has improved median
survival in small cell lung cancer (SCLC) it is increasingly
clear that long-term survival is confined to those with both
limited disease and good performance status (PS) who
constitute approximately 20% of all cases (Osterlind &
Andersen, 1986; Souhami et al., 1985). Intensive or pro-
longed therapy would be justifiable for these good prognosis
patients if it improved survival, but most patients present
with extensive disease, poor performance status or advanced
age. For these patients, chemotherapy is palliative. The
optimal duration of chemotherapy has not been established
with certainty. Cullen et al. (1986) administered six courses
of chemotherapy and the patients with no unequivocal
residual disease were randomised to either symptomatic
treatment or a further eight courses of maintenance
chemotherapy. A survival advantage was shown for those
with extensive disease receiving maintenance therapy. An
EORTC study (Splinter et al., 1986) with a similar design
showed no advantage for 12 courses of monthly maintenance
therapy.
Stopping chemotherapy early may improve the quality of
life of the patients by minimising toxicity, but in responding
patients may diminish survival unless further chemotherapy
is effective on relapse. Although response to chemotherapy
at relapse is usually clinically disappointing, Evans et al.
(1985) recorded a 55% response rate with cisplatin and
etoposide after previous treatment with cyclophosphamide,
adriamycin and vincristine.
We report here a large scale randomised trial designed to
assess the effects of duration of chemotherapy on survival in
patients with SCLC. The trial evaluates the effect of either 3
or 6 months' chemotherapy and then, at relapse, the effects
of further chemotherapy compared with symptomatic treat-
ment alone.
Patients and methods
During the period February 1982 to September 1985, 616
patients were entered into the study from the participating
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hospitals. All patients had SCLC diagnosed by histology
(from bronchial biopsy, lymph node biopsy or biopsy of a
metastasis), by cytology from bronchial brushings at broncho-
scopy or from three specimens of sputum. Patients were
required to be below 75 years, with no vascular, renal or
neurological disease which would preclude chemotherapy
and no previous malignancy during the preceding 5 years.
No exclusion was made on the basis of performance status.
Patients were not entered if they had received prior chemo-
therapy. Eight patients had had a previous lobectomy or
pneumonectomy for SCLC but had developed further dis-
ease, and 17 had received emergency radiotherapy to the
chest, spine, brain or to painful bone deposits.
Patients were staged by chest radiography, full blood
count, urea, electrolytes, liver function tests, proteins and
calcium estimations. Bone scans were routinely performed
but liver isotope or ultrasound scans ordered only if clinic-
ally indicated by abnormal liver function tests or hepato-
megaly. CT or isotope brain scans were not performed in the
absence of clinical suspicion of CNS metastasis. Bone
marrow aspiration was performed only when indicated by
abnormal blood counts. Limited disease was defined as
disease confined to one hemithorax or ipsilateral supra-
clavicular nodes. Extensive disease was more widespread
intrathoracic disease, pleural effusions or metastases.
Informed consent was obtained according to the practices
laid down by the individual ethical committee of the partici-
pating hospitals.
At diagnosis there was a double randomisation of treat-
ment. The randomisations were stratified by stage of disease
(limited or extensive). The first randomisation was to receive
either four or eight courses of initial cytotoxic chemotherapy
(short course or long course respectively). The treatment
regimen was cyclophosphamide I gm-2 i.v.; vincristine
1.4mgm-2 i.v. (maximum dose 2mg) both on day 1 and
etoposide capsules 100mg orally eight hourly on days 1-3
(total dose 900mg). Each treatment was given every 21 days
provided that the total white cell count on the day of
treatment was equal to or greater than 3,500mm3 and the
platelet count equal to, or greater than 100,000mm3. If not,
treatment dosage was reduced according to the following
schedule. If the total white cell count was 3,499-3,000, 75%
of cyclophosphamide and 700mg etoposide was given, and if
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less than 3,000, the treatment was omitted and the blood
count repeated a week later. If the platelet count was
75,000-99,999, the etoposide dose was reduced to 50%. Any
further decrease in platelet count caused the treatment to be
delayed with the blood count repeated a week later. These
dose reductions were carried over to subsequent chemo-
therapy cycles. Patients who achieved a complete or partial
response to chemotherapy after four cycles were offered
prophylactic cranial irradiation (PCI) 20Gy in five fractions
over seven days. In the short arm 77% of eligible patients
received the assigned PCI and 72% in the long arm.
The second randomisation was to receive, on disease
progression, either second-line chemotherapy or symptomatic
treatment. Relapse chemotherapy consisted of methotrexate
50 mgm 2 i.v. and doxorubicin 50mgm-2 i.v. Folinic acid
15 mg p.o. 6 hourly for four doses was given 24h after
chemotherapy to prevent methotrexate toxicity. This sche-
dule was repeated every three weeks up to a maximum of
nine courses provided there was no evidence of disease
progression. Before each course of chemotherapy the total
white cell count had to be equal to, or greater than 3,500
and the platelets equal to or greater than 100,000, or
treatment was postponed for one week or until the counts
were satisfactory. Patients randomised to receive symptoma-
tic treatment on relapse were followed as outpatients every
three weeks with clinical examination, chest X-ray and blood
investigations in the same way as those on the active relapse
treatment arm. Treatment consisted of palliative irradiation
at a dose chosen by each treatment centre for indications
including bone pain, cerebral metastases, haemoptysis, dys-
pnoea, superior vena caval obstruction or large airway
obstruction. Analgesics and corticosteroids were adminis-
tered as necessary. No cytotoxic chemotherapy was given to
patients in the symptomatic arm of the study following
initial relapse.
Response criteria
All patients had radiologically visible disease. Response was
assessed clinically, radiologically and biochemically before
each chemotherapy cycle. After four and eight cycles, restag-
ing with bone and liver scans, but not with bronchoscopy,
was carried out if clinically indicated. A complete response
was defined as complete radiological clearing of the chest X-
ray abnormality seen at diagnosis and all symptoms and
signs and biochemical abnormalities indicating metastatic
disease should have resolved completely. Fibreoptic bron-
choscopy was not routinely used to assess response. Bone
scans which were abnormal at presentation were not syste-
matically repeated since they are an unreliable indicator of
short-term response.
A partial response was a 50% or greater reduction in
tumour area as measured by two straight lines drawn across
the tumour at right angles to each other. Both complete and
partial responses had to be maintained for at least three
weeks. Stable disease was any response less than 50% and
progressive disease (or relapse) was recorded if the tumour
mass enlarged or reappeared three weeks after the last course
of chemotherapy, or during the follow-up period, or if a new
metastasis appeared. CNS relapse was confirmed by CT
brain scan and liver relapse by isotope or ultrasound scans
with deteriorating liver function tests. If biochemical
deterioration in liver function tests was detected as an
isolated feature, this was only judged to be due to metastatic
disease if the abnormality was sustained or increased at the
next planned visit. The development of changes in urea and
electrolytes possibly attributable to inappropriate secretion
of ADH was not interpreted as relapse if it occurred in
isolation. The development of bone pain was interpreted as
due to metastatic disease if associated either with appropri-
ate X-ray changes, or a positive bone scan; or an elevated
alkaline phosphatase on two consecutive visits with no
concomitant rise in the other liver enzymes. Relapse in
lymph nodes or skin lesions was confirmed by biopsy or
cytology only if there was doubt as to their nature.
After completion of short or long course chemotherapy
the patient attended every three weeks when a chest X-ray
was taken and full blood count, urea, electrolytes, liver
function tests and protein estimations and performance
status were measured. If there was evidence that relapse had
occurred, either during initial chemotherapy or on 3-weekly
follow-up, the patient was treated according to the second
randomisation.
The criteria for response and progression with the relapse
chemotherapy regimen were the same as for initial chemo-
therapy. The maximal response at any stage in treatment was
recorded. At second relapse, chemotherapy was discontinued
and the patient seen every three weeks as an outpatient and
treated palliatively without further cytotoxic drugs.
Statistical methods
On entry to the study patients were randomised to short or
long chemotherapy and to the relapse treatment. Stratifica-
tion was for disease extent only. While it is desirable, in
trials with a double randomisation, to perform the second
randomisation at the point where the treatment policy is
changed, this creates problems in a multicentre trial in small
cell lung cancer, especially for patients with extensive disease.
In the first three months of this study the second randomisa-
tion was delayed in this way, but 26 patients were not
randomised on relapse because of clinicians' reluctance to
offer further chemotherapy due to the poor quality of health
of the patient or because of refusal by the patient to accept
second-line chemotherapy. This would have created a bias in
selection of better performance status patients for the second
randomisation which would be likely to operate unequally in
the short and long initial treatment arms (patients relapsing
after prolonged treatment being more likely to refuse further
treatment). Since the aim of the trial is to assess different
treatment policies, for the rest of the trial both randomisa-
tions were made at entry and analyses are presented accord-
ing to treatment intention. All eligible patients are analysed
according to initial chemotherapy but 26 patients are
excluded from the sub-analysis of the effects of symptomatic
or second-line chemotherapy.
The number of patients required was determined before
the trial began and was based on the ability to detect a 10%
difference in overall survival from 20 to 30% at one year.
This required 551 patients to be randomised using 0.05 and
0.90 as the type I and II errors respectively (Freedman,
1982). The estimation was based on survival data in previous
studies with a 25% survival at one year (Souhami et al.,
1984). It was assumed that the survival may be less with
fewer courses of initial chemotherapy. Survival curves were
constructed according to the method of Kaplan & Meier
(1958) and statistical significance evaluated by the log-rank
test (Peto et al., 1977). To ensure that where no difference
was seen between two curves the result was likely to be a
true negative the power of the test was computed according
to Hughes (1981). The probability that the result is not a
false negative is given, in addition to the usual P value.
Results
Of the 616 patients entering the study between February
1982 and September 1985, six were subsequently excluded.
These exclusions were due to wrong diagnosis (four) and
previous malignancy within the preceding 5 years (two).
Thus 610 patients were available for analysis. The character-
istics of the 610 patients allocated at entry to each treatment
are shown in Table I. In the whole study the median age was
62 years; 68.4% were male and 31.6% female; 196 (32.1%)
had limited disease and 414 (67.9%) extensive disease.
The response rate (complete and partial) to the initial
chemotherapy is shown in Table II. These response rates are
given after four courses of chemotherapy in both groups and
after a further four cycles in the long course group. After
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Table I Patients characteristics at presentation according to assigned treatment
Short Long
According to 2nd According to 2nd
randomisation randomisation
At presentation
(total) Chemo. Sympt. At presentation Chemo. Sympt.
n 305 144a 145a 305 l oa 145a
Lim/ext (%) 31/69 34/66 32/68 33/67 35/65 32/68
PS 0 and 1 71% 75% 69% 77% 78% 77%
2-4 29% 25% 31% 23% 22% 23%
Age (years)
Median 62 61 62 63 62 63
range (31-74) (34-74) (31-74) (34-74) (34-74) (34-74)
M/F(%) 67/33 65/35 69/31 70/30 73/27 68/32
aThe total of patients who received a second randomisation is 584. This excludes 26 patients who were not
randomised at the time of relapse, from the analysis of survival after relapse (see statistical methods).
Table II Response rates to initial chemotherapy; the reponse is recorded as the best
response achieved during treatment
Short Long
Response by Response by Response by
4 courses 4 courses 8 courses
n % n % n %
Complete response 37 12.1 27 8.9 46 15.1
61% 61% 63%
Partial response 149 48.9 159 52.1 146 47.9
Stable disease 64 21.0 68 22.3 62 20.3
Progressive disease 46 15.1 41 13.4 41 13.4
(including deaths
Inevaluable 9 2.9 10 3.3 10 3.3
Total 305 305 305
and long course chemotherapy groups were similar, and
comparable numbers of patients showed progression of
disease during chemotherapy. After eight cycles the overall
response had not significantly increased but there was a
small increase in proportion of complete responders.
Eighty-eight (29%) patients did not complete the four
allocated courses of chemotherapy in the short course group
and 152 (50%) patients failed to complete long course
treatment. The reasons for failure are summarised in Table
III. The resulting distribution of numbers of courses actually
received for each intended randomisation is shown in
Table IV.
During the second randomisation, 54 patients allocated to
receive relapse chemotherapy after short course treatment
failed to receive it and 70 patients similarly failed to receive
allocated relapse chemotherapy after long course chemother-
apy. The reasons are summarised in Table V. Ninety subjects
went on to relapse chemotherapy after short course treat-
ment and 80 did so following long course chemotherapy.
Responses to relapse chemotherapy were low, with a total of
22.3% of patients showing a complete or partial response.
There was no statistical difference in the response rate in the
two groups, although the response rate was slightly higher
for those who had received short course chemotherapy
(P=0.37; Table VI) before their relapse chemotherapy.
The overall survival for all patients, based on the initial
randomisation, is shown in Figure 1. There was no signifi-
cant difference between the two survival curves (P=0.085),
but median survival in the patients randomised to long
course chemotherapy was 39 weeks, compared with 32 weeks
in those receiving short course treatment (false negative
P=0.007).
The combined results (Figure 2) show that of the four
treatment policies, four courses of chemotherapy alone gives
inferior survival to the other three treatments, which are
equivalent in outcome. Thus, if chemotherapy is given on
relapse, there is no survival disadvantage when initial treat-
ment is stopped after four cycles. In contrast, in those
Table III Reasons for not completing assigned initial chemotherapy
Short Long
(n) (n)
305 305
Withdrawals 13 26
Disease progression (including deaths)
during chemotherapy 66 114
Medical complications 1 5
Errors 6 5
Died before course 1 given 2 -
Given radiotherapy instead of 1st
course - 2
88 (29%) 152 (50%)
Table IV The number (and %) of patients stopping
initial chemotherapy at each point in the assigned
chemotherapy programme
Short (n=305) Long (n=305)
n % n %
oa 4 1.3 oa 2 0.6
1 46 15.1 1 45 14.8
2 15 4.9 2 12 3.9
3 21 6.9 3 15 4.9
4 217 71.1 4 24 7.9
5b 2 0.7 5 15 4.9
6 18 5.9
7 20 6.6
8 153 50.2 9a 1 0.3
aRandomised but not treated.
bTwo patients treated in error.
patients receiving eight cycles of initial treatment, chemo-
therapy on relapse does not significantly improve survival
compared with symptomatic treatment.
The progression-free interval was significantly longer for
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Table V Reasons for patients not receiving assigned relapse
chemotherapy
Short course Long course
Deaths during initial chemotherapy 19 24
Patient refusals 11 16
Medical contraindications 8 13
Emergency radiotherapy 3 7
Died in remission 1 0
Not yet relapsed 4 3
Reasons not known 5 7
Protocol violation 3 0
54/144(37.5%) 70/150(47%)
Table VI Response to relapse chemotherapy following short or
long course initial chemotherapy (short vs long, P=0.37)
Short Long
n % n %
Complete response 5 5.6 25.6 1 1.1 18.7 Partial response 18 20.0 14 17.6
Stable disease 39 43.3 37 46.3
Progressive disease 26 28.9 28 35.0
Inevaluable 2 2.2 0 0
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Figure 2 Overall survival for all patients according to the four
treatment intentions. (A) Short initial treatment, symptomatic
relapse treatment (n= 145, MS=30 weeks); (B) short initial
treatment, chemotherapy on relapse (n= 144, MS=38 weeks);
(C) long initial treatment, symptomatic relapse treatment
(n= 145, MS=38 weeks); (D) long initial treatment, chemo-
therapy on relapse (n=150, MS 42 weeks). A vs. B P=0.04; A
vs. C P=0.05; B vs. D P=0.84 (false negative P<0.0001).
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Figure 1 Overall survival for all patients based on the initial
randomisation. (A) Short course chemotherapy (n=305, MS 32
weeks); (B) long course chemotherapy (n=305, MS 39 weeks)
(p=0.085, false negative P=0.007).
(Figure 3). During the initial three months of the study,
when all patients were receiving chemotherapy, the rates of
relapse were similar but the rate of progression increased in
the short course group once chemotherapy had ceased. The
median progression-free intervals were 23 and 31 weeks for
short and long course patients respectively (P<0.001).
Figure 4 shows the survival curves from relapse to death.
For patients treated with short or long course chemotherapy,
who were randomised to receive symptomatic treatment only
at relapse, the curves are identical with median survivals of
11 and 12 weeks. In the patients randomised to further
chemotherapy at relapse, survival from relapse was better
than with symptomatic treatment. Median survival was 15
weeks for those allocated to long course chemotherapy, and
20 weeks for those allocated to receive short course treat-
ment. Comparing the four curves in Figure 4, survival from
relapse was longer for those patients receiving short course
and allocated to relapse chemotherapy.
When the effects of the treatment policies are separated
according to disease extent the results are as shown in Table
VII. Survival was adversely affected in patients with exten-
sive disease who were treated with four cycles of initial
chemotherapy only. A similar trend was observed for limited
stage patients but was not statistically significant. In the
BJC-D
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20 25
Figure 3 The progression free interval, for patients with stable
and responding disease, following initial chemotherapy. Median
interval following short (A) 23 weeks, n=250; long (B) 31 weeks,
n=254; P<0.001. (Vertical bars indicate patients in whom the
exact date of progression was not known.)
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Figure 4 The survival curves for relapse to death comparing
short symptomatic (A) (n = 106, MS-l 1 weeks), long and sympto-
matic (B) (n= 112, MS= 12 weeks), long and relapse chemo-
therapy (C) (n= 114, MS= 15 weeks), and short and relapse
chemotherapy (D) (n= 105, MS=20 weeks). A vs. D P<0.001. B
vs. C P=0.160.
l
0
l
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patients with limited disease the proportion of 24-month
survivors was lowest in those treated with four chemother-
apy cycles alone (although this was less apparent at 36
months). If the study is analysed further to include only the
responding population, the disadvantage of giving four
courses of chemotherapy alone becomes more apparent.
Figure 5 shows the survival curves for the responding
population randomised to receive short and symptomatic
treatment versus long and symptomatic. The survival curve
for the long treatment arm is significantly better (P=0.01)
than for the short and a difference is still apparent at two
years. The other two randomisations (Figure 6) show no
difference for the responders receiving short and relapse or
long and relapse chemotherapy (false negative P=0.002).
Toxicity data included all deaths considered to be directly
attributable to drug toxicity. There were 18 in the short
course and 11 in the long course chemotherapy arms.
However, the death rate in early cycles is not randomly
distributed during the inter-cycle period and we have shown,
and will report separately, that it is likely that chemotherapy
induced toxicity contributes to early deat-h in patients with
extensive disease. The number of reported episodes of serious
infection (WHO grade 2) was 45 during short course
chemotherapy and 70 during long. Recorded episodes of
total white cell count falling below 3,000 or a neutropenia of
Table VII Median and 2-year survival related
presentation
to disease extent
Median
survival % 2-year
(weeks) survival
Limited disease
Short 43 9.5
Long 48 8.1
Short+relapse CT 44 14.7
Short+symptomatic 42 4.3
Long+relapse CT 44 7.9
Long+symptomatic 50 8.7
Extensive disease
Short 28 1.4
Long 35 1.7
Short +relapse CT 34 1.1
Short +symptomatic 28 2.0
Long +relapse 40 1.0
Long+symptomatic 34 2.7
In limited disease patients: short and symptomatic vs short and
relapse CT P=0.200; vs long and symptomatic P=0.10; vs long and
relapse CT P=0.726. In extensive disease patients: short and symp-
tomatic vs short and relapse CT P=0.11; vs long and symptomatic
P=0.224; vs long and relapse CT P=0.01.
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Figure 5 Overall survival of responding population receiving
symptomatic treatment only at relapse. (A=short and sympto-
matic (n=89, MS=40 weeks); B=long and symptomatic (n=91,
MS=49 weeks); P=0.01).
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Figure 6 Overall survival of responding population receiving
relapse chemotherapy. (A=short and relapse (n=95, MS=48
weeks); B=long and relapse (n=97, MS=51 weeks); P=0.42).
1,000 before a course of chemotherapy was 55 during short
course and 182 during the long course treatment. Courses
were delayed a total of 71 and 217 times during short and
long course treatment respectively. Activity, mood, pain,
nausea and vomiting were assessed in detail using daily diary
cards as part of a study on quality of life which will be
reported separately. In summary, mild nausea and vomiting
occurred in almost all patients but continued longer in those
receiving eight cycles of treatment. Hair loss was universal.
Severe (WHO grade 2) mucositis occurred in 16 and 35
patients respectively, and neuropathy on four and 15
occasions during the short and long courses.
Discussion
This is one of the largest studies to address the effects of
length of chemotherapy in patients with SCLC. The major
referring centres within the multicentre group enter all
patients presenting with the disease who are judged likely to
survive a minimum of three weeks if left untreated, and the
patients are therefore representative of the disease pattern
within the community. Since the overall prognosis of SCLC
is poor (Davis et al., 1985) and many patients are elderly
and of poor performance status, the duration of chemo-
therapy is an important practical consideration. There have
been few studies addressing this question. Cullen et al. (1986)
evaluated maintenance chemotherapy versus no treatment in
patients with no unequivocal residual disease after induction
therapy and found a 16-week advantage for continuing
chemotherapy. In the EORTC study (Splinter et al., 1986)
five initial courses of chemotherapy were followed by a
randomisation in the responding population either to a
further seven courses of drug treatment or symptomatic
treatment. There was no survival advantage for further
chemotherapy in limited disease patients but a small advan-
tage for extensive disease patients. There has been no study
evaluating different durations of initial chemotherapy and
the effect of further chemotherapy after relapse. The UK
MRC Lung Cancer Working Party have compared six and
12 courses of chemotherapy and found no difference in
median or 3-year survival (D. Girling, personal
communication).
In our study, where treatment was stopped after only 12
weeks of chemotherapy in half the patients, the issue of what
to do at relapse was important because the early cessation of
therapy, especially in patients responding to treatment, may
result in an unacceptably worse survival. For this reason we
adopted a second randomisation which posed the question of
the possible benefits of second line chemotherapy. The initial
chemotherapy used widely accepted drugs active in small cell
lung cancer (Hansen & R0rth, 1979). The second line drugs,DURATION OF CHEMOTHERAPY 583
methotrexate and doxorubicin, were of different classes,
modes of action and are also active against the disease.
The results of this study show that continuing initial
chemotherapy for eight courses does not greatly increase the
response rate compared with four courses. However, stop-
ping chemotherapy after four cycles resulted in earlier
disease progression. At progression, there was a clear survi-
val advantage for second line chemotherapy in those pre-
viously receiving short course chemotherapy, but this was
less apparent in those given eight cycles. The overall study
design therefore showed that four cycles of chemotherapy
alone resulted in worse survival, but any of the other
treatment policies equal. This disadvantage of short course
chemotherapy alone was particularly obvious in the
responding population both in median and 2-year survival.
The study analysis is based on intention to treat but it
must be noted that many patients failed during initial
chemotherapy and that the clinicians in charge sometimes
felt that an individual was too ill to undergo relapse
chemotherapy. Furthermore, some patients refused chemo-
therapy on relapse. Patients dropping out of the study are
particularly likely to be patients with poor performance
status and/or extensive disease.
The study has shown that intention to treat with chemo-
therapy at relapse was harder to realise with long course
chemotherapy. Less than 50% of patients allocated to
relapse chemotherapy following long course treatment were
either willing or able to receive it. It can be concluded from
this study that the policy of stopping treatment early will
lead to earlier relapse. In the group as a whole no survival
disadvantage results provided chemotherapy is given on
relapse, and clinicians might judge that in some circum-
stances this may be a convenient treatment policy; for
example in treating elderly and poor prognosis patients or in
those with particularly severe side-effects of treatment.
However, taken together with the other studies (Cullen et al.,
1986; Evans et al., 1985; Splinter et al., 1986) the present
results show that there is a limit to the degree to which
chemotherapy can be reduced without a deterioration in
survival especially in those responding to treatment. The
data from this study and from the MRC trial indicate that,
for the majority of patients, six cycles of chemotherapy
represents adequate treatment with combination chemo-
therapy programmes similar to those used in these two
studies. Further improvements await new drug combinations
and schedules for good prognosis limited disease patients
and better palliative regimens for the others.
This study was supported by the Cancer Research Campaign.
Walter Gregory gave invaluable help in statistical analysis. The
computing facilities were made available by the Imperial Cancer
Research Fund. Miss Angela Betchley and Miss Piera Cassettari
typed the manuscript with great care. We would like to thank the
following physicians for referring cases to this trial: Dr J.R. Govan,
Dr G.H. Wiggins, Dr D. Phillips, Dr A. Willis, Dr C. Trask, Dr R.
Weatherstone, Dr D.W. Empey, Dr G.W. Bradley, Dr J. Millard,
Dr P. Cole, Dr J.V. Collins, Dr R.K. Knight, Dr M. Apps, Dr R.A.
Storring, Dr J. Utting, Dr J. Warren, Dr P.R. Studdy, Dr J.
Riordan, Dr M.W. McNicol, Dr J. Meadway, Dr M. Harrier, Dr
W.A.C. McAllister, Dr M.E. Hodson, Dr A. Newman-Taylor, Dr
R.A. Banks, Dr L.R. Bagg, Dr W.P.U. Kennedy, Dr I. Williams, Dr
0. McCarthy, Dr N. Eiser, Dr G.M. Cochrane, Dr S. Steel, Dr
M.R. Hetzel, Dr J. Milledge, Dr J. Waller, Dr M.E. Turner-
Warwick, Dr M. Green and Dr A.H. Diamond.
References
CULLEN, M. MORGAN, D., GREGORY, W. & 11 others (1986).
Maintenance chemotherapy for anaplastic small cell carcinoma
of the bronchus: a randomised controlled trial. Cancer Chem.
Plharniacol., 17, 157.
DAVIS, S., WRIGHT, P.W., SCHULMAN, S.F., SCHOLES, D.,
THORNING, D. & HAMMAR S. (1985). Long-term survival in
small-cell carcinoma of the lung: a population experience. J.
Clin. Oncol., 3, 80.
EVANS, W.K., OSOBA, D., FELD, R., SHEPHERD, F.A., BAZOS, M.J. &
DEBOER, G. (1985). Etoposide (VP-16) and cisplatin: an effective
treatment for relapse in small cell lung cancer. J. Clin. Oncol., 3,
65.
FREEDMAN, L.S. (1982). Tables of the number of patients required
in clinical trials using the Logrank test. Stat. Med., 1, 121.
HANSEN, H.H. & R0RTH, M. (1979). Lung cancer. In Cancer
Chemotherapy, Pinedo, H.M. (ed.) p. 267. Excerpta Medica:
Amsterdam.
HUGHES, D.J. (1981). Approximate error probabilities for the log
rank test. Working paper of Research Centre for Mathematical
Modelling of Clinical Trials, University of Warwick.
KAPLAN, E.L. & MEIER, P. (1958). Non parametric estimation from
incomplete observations. J. Am. Stat. Assoc., 53, 457.
OSTERLIND, K. & ANDERSEN, P.K. (1986). A model for survival in
small cell lung cancer. A study of prognostic factors in 874
patients treated with chemotherapy with or without irradiation.
Cancer Res., 46, 4189.
PETO, R., PIKE, M.C., ARMITAGE, P. & 7 others (1977). Design and
analysis of randomised clinical trials requiring prolonged obser-
vation of each patient. Br. J. Cancer, 35, 1.
SOUHAMI, R.L., BRADBURY, I., GEDDES, D.M., SPIRO, S.G.,
HARPER, P.G. & TOBIAS, J.S. (1985). The prognostic significance
of laboratory parameters measured at di4gnosis in small cell
carcinoma of the lung. Cancer Res., 45, 2878.
SOUHAMI, R.L., GEDDES, D.M., SPIRO, S.G. & 5 others (1984).
Radiotherapy in small cell cancer of the lung treated with
combination chemotherapy: a controlled trial. Br. Med. J., 288,
1643.
SPLINTER, T., McVIE, J.G., DELASSIO, 0. & 20 others (1986).
Induction versus induction plus maintenance chemotherapy in
small cell lung cancer. Am. Soc. Clin. Oncol., C188.